BR112018002172A2 - promotores para intensificar a expressão em poxvírus - Google Patents

promotores para intensificar a expressão em poxvírus

Info

Publication number
BR112018002172A2
BR112018002172A2 BR112018002172A BR112018002172A BR112018002172A2 BR 112018002172 A2 BR112018002172 A2 BR 112018002172A2 BR 112018002172 A BR112018002172 A BR 112018002172A BR 112018002172 A BR112018002172 A BR 112018002172A BR 112018002172 A2 BR112018002172 A2 BR 112018002172A2
Authority
BR
Brazil
Prior art keywords
enhance
promoters
expression
poxvirus expression
poxvirus
Prior art date
Application number
BR112018002172A
Other languages
English (en)
Other versions
BR112018002172A8 (pt
BR112018002172B1 (pt
Inventor
Delcayre Alain
Rountree Ryan
Li Zengji
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BR112018002172A2 publication Critical patent/BR112018002172A2/pt
Publication of BR112018002172A8 publication Critical patent/BR112018002172A8/pt
Publication of BR112018002172B1 publication Critical patent/BR112018002172B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção diz respeito a um ou mais promotores e/ou cassetes de expressão que podem ser utilizados para intensificar a expressão de um gene heterólogo, tal como brachyury. em particular, o um ou mais promotores e/ou cassetes de expressão intensificam a expressão de genes heterólogos como parte de um vetor viral, tal como um poxvírus.
BR112018002172-5A 2015-07-31 2016-07-28 Promotores para intensificar a expressão em poxvírus BR112018002172B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199681P 2015-07-31 2015-07-31
US62/199,681 2015-07-31
PCT/IB2016/001183 WO2017021776A1 (en) 2015-07-31 2016-07-28 Promoters for enhancing expression in poxviruses

Publications (3)

Publication Number Publication Date
BR112018002172A2 true BR112018002172A2 (pt) 2018-09-18
BR112018002172A8 BR112018002172A8 (pt) 2024-02-15
BR112018002172B1 BR112018002172B1 (pt) 2024-06-25

Family

ID=

Also Published As

Publication number Publication date
JP2018521651A (ja) 2018-08-09
AU2016303378B2 (en) 2021-12-23
EP3329016A1 (en) 2018-06-06
IL256869B (en) 2022-07-01
BR112018002172A8 (pt) 2024-02-15
KR20180033498A (ko) 2018-04-03
ZA201800104B (en) 2022-04-28
RU2018106643A (ru) 2019-08-28
JP6851364B2 (ja) 2021-03-31
CN107922981A (zh) 2018-04-17
ES2901468T3 (es) 2022-03-22
WO2017021776A1 (en) 2017-02-09
RU2753884C2 (ru) 2021-08-24
US20180216134A1 (en) 2018-08-02
DK3329016T3 (da) 2022-01-10
MX2018001055A (es) 2018-05-17
SG10202000447YA (en) 2020-03-30
HK1254405A1 (zh) 2019-07-19
RU2018106643A3 (pt) 2020-01-30
CA2990549A1 (en) 2017-02-09
AU2016303378A1 (en) 2018-01-25
IL256869A (en) 2018-03-29
EP3329016B1 (en) 2021-10-20
CN107922981B (zh) 2022-02-25
US11753652B2 (en) 2023-09-12
KR102565284B1 (ko) 2023-08-08

Similar Documents

Publication Publication Date Title
MX2021005226A (es) Regulacion de expresion genica mediada por nucleasa.
PH12018501159A1 (en) Composition and methods for immunooncology
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EA201690403A1 (ru) Композиции и способы для модулирования рнк
EP4403229A3 (en) Expression of pten-long with oncolytic viruses
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
CR20140538A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modificación de la transcripción dirigida por arn
JO3765B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18 (18hpv)
MY181175A (en) Therapeutic hpv16 vaccines
DOP2022000085A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2017016400A (es) Vectores para uso en un sistema de coexpresion inducible.
BR112019004594A2 (pt) terapia genética para pacientes com anemia de fanconi
MY165601A (en) Heat-absorbent and radiant steel sheet, and heat-absorbent and radiant member
MX2017016623A (es) Variantes de quimosina con propiedades mejoradas.
EP3414650A4 (en) SOCIAL KEYBOARD
MX2018002366A (es) Variantes de quimosina con propiedades mejoradas.
MX2021006326A (es) Inhibidores de pcna.
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
EP3373938A4 (en) NOVEL RNA-BASED VECTOR SYSTEM FOR TEMPORARY AND STABLE GENE EXPRESSION
MY187959A (en) Reactor
BR112017024855A2 (pt) métodos de produção de aldc
EP3305904A4 (en) PROMOTER DERIVED FROM POXVIRUS, AND VECTOR COMPRISING SAME
DK2921171T3 (da) Oftalmiske, intraartikulære eller intravesikale præparater indeholdende n-acyl-ethanolaminer
MX2019006551A (es) Terapia génica para mucopolisacaridosis de tipo ii.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2016, OBSERVADAS AS CONDICOES LEGAIS